# A Study to Evaluate the Efficacy and Safety of IBI302 in Subjects With nAMD

> **NCT05972473** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.** · enrollment: 600 (actual)

## Conditions studied

- Neovascular Age-related Macular Degeneration

## Interventions

- **DRUG:** Aflibercept Ophthalmic
- **BIOLOGICAL:** IBI302

## Key facts

- **NCT ID:** NCT05972473
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-09-21
- **Primary completion:** 2027-02-28
- **Final completion:** 2027-04-30
- **Target enrollment:** 600 (ACTUAL)
- **Last updated:** 2025-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05972473

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05972473, "A Study to Evaluate the Efficacy and Safety of IBI302 in Subjects With nAMD". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT05972473. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*